ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

risvutatug rezetecan

Also written as “HS-20093”, “HS-20093 for Injection” and “Risvutatug rezetecan (Ris-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H3. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Osteosarcoma · Neoplasms · Prostatic Neoplasms, led by 3 companies.

Drug pageRisvutatug rezetecan: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 6, 202430 company-led studies, 26 open or runningLicense: Hansoh → GSK, Dec 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Groupits history only2117 open or runningphase 3since Jul 6, 2024Feb 18, 2022Dec 30, 2026phase 1 · NCT06699576
GlaxoSmithKline88 open or runningphase 3since Jul 30, 2025Mar 3, 2022Nov 5, 2027phase 3 · NCT07099898
Jiangsu HengRui Medicineits history only11 open or runningphase 2since Nov 13, 2025Nov 13, 2025Dec 2028phase 2 · NCT07230106
  • Named in GlaxoSmithKline’s own pipeline as risvutatug rezetecan GSK5764227, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20093 (B7-H3 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Dec 20, 2023 · Source: GSK, Dec 20, 2023

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05277051 · 152 enrolled · United States, Australia, Canada and more
  2. Dec 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  3. Aug 9, 2024Phase 1 study in NeoplasmsNCT06551142 · 845 planned · United States, Argentina, Canada and more
  4. Mar 13, 2025Phase 2 study in Gastrointestinal NeoplasmsNCT06885034 · 346 planned · United States, Australia, Belgium and more
  5. Jul 10, 2025Named risvutatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20093, GSK5764227
  6. Jul 30, 2025Phase 3 study in Lung NeoplasmsNCT07099898 · 420 planned · United States, Argentina, Australia and more
  7. Dec 2, 2025Phase 1 study in NeoplasmsNCT07277270 · 83 planned · United States, Australia, Canada and more
  8. May 11, 20262 phase 2 studiesNCT07602777, NCT07602855
  9. Aug 28, 2026Phase 3 study in Prostatic NeoplasmsNCT07802704 · 684 planned · Australia, Canada, Japan and more
  10. Sep 25, 2026Primary completion moved from 2026-07-13 to 2028-02-14Date moved laterphase 1 · +19 months · NCT07277270
  11. Oct 19, 2026Primary completion moved from 2028-01-10 to 2029-01-09Date moved laterphase 2 · +12 months · NCT06885034

Ahead

  1. Nov 5, 2027Primary completion: phase 2 study in SarcomaNCT07602777
  2. Nov 5, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT07099898
  3. Feb 14, 2028Primary completion: phase 1 study in NeoplasmsNCT07277270
  4. Oct 16, 2028Primary completion: phase 1 study in NeoplasmsNCT06551142

TargetBeta

“ADC targeting B7-H3”the company's pipeline, read by Claude · source
“B7-H3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of risvutatug, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) covalently ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Elfetabart DrozuntecanruleBioNTechphase 33
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

All 8 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07802704Prostatic Neoplasms · Australia, Canada, Japan and more3RecruitingDec 5, 2029684
NCT07602855Lung Neoplasms · United States, Japan2RecruitingJun 22, 2029184
NCT07602777Sarcoma · United States, Canada, France and more2RecruitingNov 5, 202764
NCT07277270Neoplasms · United States, Australia, Canada and more1RecruitingFeb 14, 202883
NCT07099898Lung Neoplasms · United States, Argentina, Australia and more3RecruitingNov 5, 2027420
NCT06885034Gastrointestinal Neoplasms · United States, Australia, Belgium and more2RecruitingJan 9, 2029346
NCT06551142Neoplasms · United States, Argentina, Canada and more1RecruitingOct 16, 2028845
NCT05277051Neoplasms · United States, Australia, Canada and more1Active, not recruitingJun 30, 2026152

How it is read

Names in the registry

  • “HS-20093”, 15 entries
  • “HS-20093 for Injection”, 4 entries
  • “Risvutatug rezetecan (Ris-Rez)”, 2 entries
  • “GSK5764227”, 2 entries
  • “Ris-Rez”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.